Effect of Nigella sativa and wheat germ oils on scopolamine-induced memory impairment in rats  by El-Marasy, Salma A. et al.
Bulletin of Faculty of Pharmacy, Cairo University (2012) 50, 81–88Cairo University
Bulletin of Faculty of Pharmacy, Cairo University
www.elsevier.com/locate/bfopcu
www.sciencedirect.comORIGINAL ARTICLEEﬀect of Nigella sativa and wheat germ oils
on scopolamine-induced memory impairment in ratsSalma A. El-Marasy a,*, Siham M. El-Shenawy a, Aiman S. El-Khatib b,
Osama A. El-Shabrawy a, Sanaa A. Kenawy ba Department of Pharmacology, National Research Centre, Cairo, Egypt
b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, EgyptReceived 17 November 2011; accepted 9 May 2012
Available online 23 June 2012*
N
E
Pe
U
11
htKEYWORDS
Nigella sativa oil;
Wheat germ oil;
Scopolamine;
Memory impairment;
RatsCorresponding author. Ad
ational Research Centre, 126
-mail address: salma_el_mar
er review under responsibi
niversity
Production an
10-0931 ª 2012 Faculty of P
tp://dx.doi.org/10.1016/j.bfopdress: D
22 Cairo
asy@hot
lity of F
d hostin
harmacy
cu.2012.Abstract Aim: To investigate the possible memory enhancing effects of Nigella sativa oil (NSO)
and wheat germ oil (WGO) on scopolamine-induced amnesic rats.
Methods: Male Wistar rats received either saline or scopolamine (16 mg/kg, i.p.). The other three
groups were pretreated with NSO (1 ml/kg, p.o.), WGO (170 mg/kg, p.o.) or donepezil used as a
reference drug (10 mg/kg, p.o.) for 14 days before scopolamine injection. Cognitive and biochemical
measurements were then assessed.
Principal results: NSO and WGO treated rats signiﬁcantly reversed scopolamine-induced deﬁcit of
spatial and non-spatial working memory impairment in the T maze alternation task and object rec-
ognition test, respectively. Administration of NSO prior to scopolamine showed a signiﬁcant
decrease in malondialdehyde (MDA) and increase in Glutathione (GSH) brain contents to be similar
to that observed in donepezil group. It did not alter cholinesterase activity and showed a signiﬁcant
decrease in brain tumor necrosis factor-alpha (TNF-a) content to be similar to donepezil-treated rats.
Scopolamine-demented rats pretreated with WGO did not change MDA brain content signiﬁcantly
as compared to scopolamine and donepezil groups. WGO-treated rats showed a signiﬁcant increase
in GSH to a level similar to that observed in the donepezil group, it showed a signiﬁcant decrease in
cholinesterase activity as compared to scopolamine group and signiﬁcantly elevated brain TNF-a
content when compared to donepezil group.epartment of Pharmacology,
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82 S.A. El-Marasy et al.Conclusions: Memory enhancing effect of NSO in the present study might be due to its antioxidant
and anti-inﬂammatory activities, while that of WGO might be via its antioxidant and anticholines-
terase activities.
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reserved.1. Introduction
Dementia is characterized by a loss of or decline in memory
and other cognitive abilities. Alzheimer’s disease (AD) is one
of the most common subtypes of dementia.1 It is characterized
by deposition of amyloid plaques, neuroﬁbrillary tangles, cere-
bral oxidative stress, inﬂammation and impaired neuronal
function.2
The operant mechanism of AD in the elderly population is
related to cholinergic system dysfunctions such as the loss of
cholinergic neurons in the basal forebrain and hippocampus.3
Acetylcholine functions as the principal neurotransmitter and
its decreased release also results in learning deﬁcits.4 Both ace-
tylcholinesterase (AChE) and butyrylcholinesterase (BChE)
are best known to hydrolyze acetylcholine rapidly.5 In patients
with AD the level of AChE activity declines and the activity of
BChE increase in certain brain regions. Cholinesterase inhibi-
tion is the most used treatment for the symptoms of AD and
AChE as well as BChE are therapeutic targets for improving
the cholinergic deﬁcit.6
Scopolamine, a muscarinic receptor antagonist, have pro-
found amnesic effects in a variety of learning paradigms and
is considered a useful experimental approach to investigate
the mechanisms involved in cognitive impairment observed
in AD.7 Scopolamine also mediates cholinergic deﬁcit through
oxidative stress8 and neuroinﬂammation.9
Acetylcholinesterase inhibitors (AChEIs) e.g. donepezil, riv-
astigmine and galantamine, are the most effective pharmaco-
therapeutic agents for AD. However, these agents also cause
undesirable side effects that limited their use.10 Donepezil also
suppressed oxidative stress in the animal model of dementia.11
Furthermore, it exerts its therapeutic effect in AD not only by
inhibition of AChE but also by its anti-inﬂammatory effect.12,13
NSO has been extensively reported to exhibit protective ef-
fect against many diseases depending on its high antioxidant14
as well as anti-inﬂammatory activities.15 Moreover, reactive
oxygen species are implicated in the mechanism of several neu-
rodegenerative diseases such as AD16 therefore NSO could be
used as a possible remedy for cognitive disorders.
WGO has the highest tocopherol content of all vegetable
oils, and particularly the highest content of a-tocopherol (vita-
min E), which represents around 60% of the total content.17
Vitamin E is a potent antioxidant agent that has been de-
scribed to protect the brain from oxidative stress by directly
scavenging toxic radicals18 and ameliorate the brain impair-
ment process underlying aging.19 Moreover brain AChE was
markedly reduced by supplementation with vitamin E.20
The present study was constructed in order to assess the
inﬂuence of NSO and WGO on behavioral alterations in de-
mented rats. Donepezil was used as a reference drug.Moreover,
their effects on brain oxidative stress indices, cholinergic deﬁcit
and inﬂammation were also evaluated.2. Materials and methods
2.1. Animals
Male albino Wistar rats weighing 120–150 g were used
throughout the experiment. They were obtained from the ani-
mal house colony of the National Research Centre (Dokki,
Cairo, Egypt) and were housed for at least one week in the
laboratory room prior to testing under standard housing con-
ditions. Animals were fed standard laboratory pellets with
water ad libitum. All animal procedures were performed in
accordance with the Ethics Committee of the National
Research Centre, Egypt. Registration number (09/189).
2.2. Drugs and chemicals
Scopolamine hydrobromide was purchased from Sigma–
Aldrich (MO, USA) and was dissolved in saline (0.9% NaCl).
Donepezil hydrochloride was purchased from Pﬁzer (Giza,
Egypt) and was freshly prepared in 1% tween 80 in water.
NSO and WGO were obtained as a gift from Mepaco (Shar-
kia, Egypt). WGO was used as 1% v/v oil in water emulsion.
2.3. Treatments
Rats were randomly allocated into ﬁve groups (10 rats/group
in the T maze alternation task and 8 rats/group in the object
recognition test) as follows: group I received saline and served
as normal while group II received scopolamine (16 mg/kg,
i.p.)21 and served as control. Both groups received saline for
14 days. Groups III–V received donepezil (10 mg/kg, p.o.),22
NSO (1 mg/kg, p.o.)23 (equivalent to 0.92 mg/kg) or WGO
(170 mg/kg, p.o.),24 respectively for 14 days. Scopolamine
was administered as a single dose 30 min after the last admin-
istration in groups II–V.
2.4. Cognitive measurements
2.4.1. T maze alternation task
The spatial alternation maze was designed as described else-
where.25 Rats were fasted for 23 h before the onset of behavioral
training and refed again for 1 h later. Rats were then habituated
for 5 successive days to the maze and the food reward (5 min of
exposure to the maze each day, with food pellets initially scat-
tered along the ﬂoor then food was gradually restricted to both
arms of the maze) throughout drug treatment.26,27
The T maze procedure was modiﬁed based on the results of a
pilot study, where each rat received throughout drug treatment 2
daily alternation sessions, incremented to 4 sessions and up to 6
daily sessions thereafter.Then ratswere trained for 3 days and re-
ceived 6 sessions daily. Each session consisted of 2 trials with 30-s
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was rewardedwith a food pellet for entry into either of the choice
arms.After eating thepellet the ratwas returnedback to thehold-
ing box. The choice points and the entire maze were wiped with
alcohol solution between trials. On the second trial, a reward
was placed only in the choice arm opposite to that visited in the
ﬁrst trial. The intertrial interval was approximately 2 min.
A correct choice was deﬁned as the rat alternated the arm
(entered its four paws into the choice arm opposite to that en-
tered in the ﬁrst trial). The T maze alternation task was also
assessed 15 min following scopolamine injection.
% of basal correct trials ¼ ½number of correct trials after
scopolamine treatment=baseline
of correct trialsðmean of 3 days
training throughout drug
treatmentÞ  100:
%of correct trialsð%of controlÞ ¼ ðsquare root transformed
% of basal correct trials
of normal or treated
groups=square root
transformed% of basal
correct trials of control
groupÞ100:
Square root transformed percent was calculated according
to previous method.28
2.4.2. Object recognition test
The test apparatus was designed as described elsewhere.29
Three days before testing, each rat was allowed to explore
the apparatus for 2 min, while on the testing day, 30 min fol-
lowing scopolamine injection, a session of two trials, 2-min
each was allowed. In the ‘‘sample’’ trial (T1), two identical ob-
jects were placed in two opposite corners of the apparatus. A
rat was placed in the apparatus and was left to explore these
two identical objects. After T1, the rat was placed back in its
home cage and an inter-trial interval of 1 h was given. Subse-
quently, the ‘‘choice’’ trial (T2) was performed. In T2, a new
object (N) replaced one of the objects that were presented in
T1, then rats were exposed again to two different objects: the
familiar (F) and the new one (N).
Exploration was deﬁned as follows: directing the nose to-
ward the object at a distance of no more than 2 cm and/or
touching the object with the nose.
From this measure, a series of variables were then calcu-
lated: the total time spent in exploring the two identical objects
in T1, and that spent in exploring the two different objects, F
and N in T2. The discrimination between F and N in T2 was
measured by comparing the time spent in exploring the F with
that spent in exploring the N. DI is the discrimination index
and represents the difference in exploration time expressed as
a proportion of the total time spent exploring the two objects
in T2. DI was then calculated; DI = N  F/N + F.
2.5. Brain homogenate preparation
Rats were sacriﬁced by decapitation immediately after object
recognition test. The whole brain was carefully excised, immedi-
ately weighed to avoid drying and stored at 80 C. Brain washomogenized in ice-cold phosphate buffer (20% w/v). The
homogenate was used for determination of brain contents of
MDA, GSH, brain cholinesterase activity and TNF-content.
2.6. Determination of biochemical markers in brain homogenate
Brain MDA content was determined according to the method
of Ruiz-Larrea et al.30 the supernatant was read spectrophoto-
metrically at 532 nm and MDA brain content was expressed as
nmol/g tissue. The brain GSH content was determined accord-
ing to the methods described elsewhere.31,32 Calculation of
GSH content was based on a standard glutathione curve and
expressed as lmol/g tissue. Brain cholinesterase activity was
determined colorimetrically using Quimica Clinica Aplicada
S.A. kit according to the method described previously.33 The
mean of absorbance change per 30 s (DA/30 s) was determined
for every reading. Cholinesterase activity was expressed as U/g
tissue. TNF-a was estimated using rat speciﬁc immunoassay kit
(RayBio Rat TNF-alpha ELISA) according to the method
described previously.34 The intensity of the colored product is
directly proportional to the concentration of rat TNF-a using
a microplate reader set at 450 nm and expressed as ng/g tissue.
The sample values are then read off the standard curve.
2.7. Statistical analysis
Data concerning the T maze alternation task, object recogni-
tion test and biochemical parameters were expressed as
mean ± SEM. Comparison between more than two groups
was carried out using one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test. Comparison
with baseline in the T maze alternation task was carried out
by two-way ANOVA followed by Bonferroni multiple com-
parison test. When comparing within each group the explora-
tion times of (T1 vs. T2) in the object recognition test and the
exploration times of the F and N objects in T2, Student’s t-test
was used. All analyses utilized Graph pad Prism 5.0 statistical
package for Windows (Graphpad Software Inc., San Diego,
USA). Statistical signiﬁcance was set at P< 0.05.3. Results
3.1. Effect of NSO or WGO on scopolamine-induced memory
impairment in the T maze alternation task
Treatment of rats with scopolamine signiﬁcantly reduced cor-
rect trials to be 44% of their basal correct choices at 30-s inter-
val delay and signiﬁcantly reduced correct trials to be 67% of
that in normal rats (Table 1 and Fig. 1).
Daily oral administration of NSO (0.92 mg/kg) or WGO
(170 mg/kg) for 14 consecutive days before scopolamine signif-
icantly increased the correct trials to be 142% and 147% of
that in the control scopolamine group, respectively to be sim-
ilar to that of the donepezil group (Fig. 1).
3.2. Effect of NSO or WGO on scopolamine-induced memory
impairment in the object recognition test
Within T1 and T2, no differences in total exploration time
were seen among the different groups. Comparing with the
Figure 1 Effect of NSO or WGO on scopolamine-induced
memory impairment in the T maze alternation task. Rats received
14 daily administration of NSO (0.92 mg/kg, p.o.), WGO
(170 mg/kg, p.o.) or donepezil (10 mg/kg, p.o.) used as a standard
drug. The normal and control groups similarly received saline.
Scopolamine was administered as a single dose (16 mg/kg, i.p.)
30 min after the 14th treatment of all groups except the normal
one. Fifteen minutes later the task was carried out. Data are
expressed as square- root transformed % of basal correct trials
(n= 10). Statistical analysis was carried out by one-way ANOVA
followed by Tukey’s multiple comparison test.*Signiﬁcant differ-
ence from normal group at p< 0.05. @Signiﬁcant difference from
control (scopolamine) group at P< 0.05. Signiﬁcant difference
from donepezil group at p< 0.05.
Table 1 Inﬂuence of 14 daily administration of NSO or WGO on performance of scopolamine-treated rats in the T maze alternation
task.
Treatment Parameters
Spatial working memory
Correct trials
Baseline (mean of 3 days training)
throughout drug treatment
After scopolamine
treatment
Normal (saline) 4.83@ ± 0.26 4.70@ ± 0.30
Control (Scopolamine) (16 mg/kg, i.p.) 4.73@ ± 0.27 2.10* ± 0.23
Donepezil (10 mg/kg, p.o.) + Scopolamine (16 mg/kg, i.p.) 5.47@ ± 0.12 5.00@ ± 0.30
NSO (0.92 mg/kg, p.o.) + Scopolamine (16 mg/kg, i.p.) 5.17@ ± 0.20 4.60@ ± 0.34
WGO (170 mg/kg, p.o.) + Scopolamine (16 mg/kg, i.p.) 5.23@ ± 0.22 4.90@ ± 0.28
Data represent means ± SEM (n= 10). Statistical analysis was carried out by two-way ANOVA followed by Bonferroni multiple comparison
test.
*Signiﬁcant difference from baseline at P< 0.05.
@Signiﬁcant difference from correct trials after scopolamine treatment at P< 0.05.
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in T2 was observed in all rats except those treated with scopol-
amine (Fig. 2). Rats treated with scopolamine explored the no-
vel and familiar objects similarly. Exploration time in T2
showed that NSO orWGO-treated rats were similar to donepe-
zil-treated rats and explored the new object signiﬁcantly more
than the familiar one as shown in Fig. 3. DI revealed that all
rats, except those treated with scopolamine, signiﬁcantly dis-
criminated the new object better than the familiar one (Fig. 4).3.3. Malondialdehyde brain content
The MDA content expressed as nmol/g tissue was signiﬁcantly
higher in scopolamine-treated rats 164.01 ± 1.54 as compared
to the normal group 150.13 ± 2.92. NSO administered for 14
successive days before scopolamine resulted in a signiﬁcant
decrease in MDA content to 87% of scopolamine control
group and restored MDA brain content to be similar to
donepezil. WGO did not show any change in MDA content
when compared to normal, scopolamine and donepezil groups
(Table 2).
3.4. Glutathione brain content
A signiﬁcant decrease in GSH content was observed in the
scopolamine-treated group 1.57 ± 0.03 as compared to the
normal group 2.45 ± 0.09 expressed as lmol/g tissue. NSO
and WGO administered for 14 successive days before scopol-
amine showed a signiﬁcant increase in GSH brain content to
142% and 160% of scopolamine control group, respectively.
NSO and WGO increased brain GSH content to a similar level
as the donepezil group (Table 2).
3.5. Brain cholinesterase activity
There was a signiﬁcant increase in cholinesterase activity in the
scopolamine-treated group 475.72 ± 40.90 as compared to the
normal group 355.16 ± 28.74, expressed as U/g tissue. NSO
did not alter cholinesterase activity when compared to the sco-
polamine and donepezil groups. WGO administered before
scopolamine resulted in a signiﬁcant decrease in cholinesterase
activity to 72% of scopolamine control group (Table 3).
3.6. Tumor necrosis factor-alpha brain content
Scopolamine administered as a single intraperitoneal dose
(16 mg/kg) signiﬁcantly increased TNF-a content to be 7.07
± 0.56 whereas the normal group was 2.68 ± 0.07, expressed
as ng/g tissue. NSO administered for 14 successive days before
scopolamine resulted in a signiﬁcant decrease in TNF-a content
to 26% of scopolamine control group. NSO decreased the
Figure 2 Effect of NSO or WGO on exploration time in T1 and
T2 in scopolamine-induced memory impairment in rats using the
object recognition test. Rats received 14 daily administration of
NSO (0.92 mg/kg, p.o.), WGO (170 mg/kg, p.o.) or donepezil
(10 mg/kg, p.o.) used as a standard drug. The normal and control
groups similarly received saline. Scopolamine was administered as
a single dose (16 mg/kg, i.p.) 30 min after the 14th treatment of all
groups except the normal one. T1 was performed 30 min following
scopolamine. T2 was carried out 60 min following T1. Results are
expressed as mean ± SEM (n= 8). Statistical analysis was carried
out by Student’s t-test. *Signiﬁcant difference from the corre-
sponding T1 group at P< 0.05.
Figure 3 Effect of NSO or WGO on the exploration time of the
familiar (F) vs. the novel object (N) in T2 in the object recognition
test. Rats received 14 daily administration of NSO (0.92 mg/kg,
p.o.), WGO (170 mg/kg, p.o.) or donepezil (10 mg/kg, p.o.) used
as a standard drug. The normal and control groups similarly
received saline. Scopolamine was administered as a single dose
(16 mg/kg, i.p.) 30 min after the 14th treatment of all groups
except the normal one. T1 was performed 30 min following
scopolamine. T2 was carried out 60 min following T1. Data
represent mean ± SEM (n= 8). Statistical analysis was carried
out by Student’s t-test. *Signiﬁcant difference from the corre-
sponding N group at P< 0.05.
Figure 4 Effect of NSO or WGO on discrimination index (DI) of
scopolamine-induced memory impairment in rats using the object
recognition test. Rats received 14 daily administration of NSO
(0.92 mg/kg, p.o.), WGO (170 mg/kg, p.o.) or donepezil (10 mg/kg,
p.o.) used as a standard drug. The normal and control groups
similarly received saline. Scopolamine was administered as a single
dose (16 mg/kg, i.p.) 30 min after the 14th treatment of all groups
except the normal one. T1 was performed 30 min following
scopolamine. T2 was carried out 60 min following T1. Data
represent mean ± SEM (n= 8). Statistical analysis was carried
out by one-way ANOVA followed by Tukey’s multiple comparison
test.*Signiﬁcant difference from normal group at p< 0.05. @Sig-
niﬁcant difference from control (scopolamine) group at P< 0.05. 
Signiﬁcant difference from donepezil group at p< 0.05.
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did not show any change in TNF-a content when compared tocontrol scopolamine group and signiﬁcantly elevated TNF-a
content when compared to donepezil group (Table 4).
4. Discussion
NSO in this study signiﬁcantly antagonized scopolamine-in-
duced cognitive dysfunction in the T maze alternation task.
NSO ameliorating effects on rats’ performance in the T maze
alternation task were similar to donepezil, indicating that
NSO attenuated the short-term memory deﬁcit induced by sco-
polamine in rats.
Similarly, in the current study WGO signiﬁcantly reversed
scopolamine-induced cognitive dysfunction in the T maze
alternation task and enhanced rats’ performance to be similar
to donepezil and this indicate that WGO restored the spatial
working memory in demented rats. As WGO is the natural
supplement of vitamin E, so our result is in agreement with
another study which stated that vitamin E attenuated
scopolamine’s effect on memory retention of passive avoidance
learning in rats.35 Moreover, vitamin E ameliorated memory
impairments during the normal aging process in both humans
and animals.36,37
The current object recognition paradigm revealed that no
differences were observed among the different populations
within T1 and T2, while the overall exploratory activity of all
experimental groups in T2 was reduced as compared to their
performance in T1 except in scopolamine treated rats. This
Table 2 Effect of NSO or WGO on brain MDA and GSH contents in scopolamine-treated rats.
Groups Parameters
MDA (nmol/g tissue) GSH (umol/g tissue)
Normal (saline) 150.13@ ± 2.92 2.45@ ± 0.09
Control (Scopolamine) (16 mg/kg, i.p.) 164.01*, ± 1.54 1.57*, ± 0.03
Donepezil (10 mg/kg, p.o.) + Scopolamine (16 mg/kg, i.p.) 148.40@ ± 1.88 2.78@ ± 0.21
NSO (0.92 mg/kg, p.o.) + Scopolamine (16 mg/kg, i.p.) 143.21@ ± 4.35 2.23@ ± 0.21
WGO (170 mg/kg, p.o.) + Scopolamine (16 mg/kg, i.p.) 154.90 ± 3.52 2.51@ ± 0.15
Data represent means ± SEM (n= 6). Statistical analysis was carried out by one-way ANOVA followed by Tukey’s multiple comparison test.
*Signiﬁcant difference from normal group at P< 0.05.
@Signiﬁcant difference from control (scopolamine) group at P< 0.05.
Signiﬁcant difference from donepezil group at P< 0.05.
Table 3 Effect of NSO or WGO on brain cholinesterase
activity of scopolamine-treated rats.
Groups Parameters
Cholinesterase
activity (U/g tissue)
Normal (saline) 355.16@ ± 28.74
Control (Scopolamine)
(16 mg/kg, i.p.)
475.72* ± 40.90
Donepezil (10 mg/kg, p.o.) +
Scopolamine (16 mg/kg, i.p.)
379.27 ± 6.39
NSO (0.92 mg/kg, p.o.) +
Scopolamine (16 mg/kg, i.p.)
420.33 ± 18.72
WGO (170 mg/kg, p.o.) +
Scopolamine (16 mg/kg, i.p.)
344.08@ ± 30.95
Data represent means ± SEM (n= 6). Statistical analysis was
carried out by one-way ANOVA followed by Tukey’s multiple
comparison test.
*Signiﬁcant difference from normal group at P< 0.05.
@ Signiﬁcant difference from control (scopolamine) group at
P< 0.05.
Table 4 Effect of NSO or WGO on TNF-a content of
scopolamine-treated rats.
Groups Parameters
TNF-a (ng/g tissue)
Normal (saline) 2.68@ ± 0.07
Control (Scopolamine)
(16 mg/kg, i.p.)
7.07*, ± 0.56
Donepezil (10 mg/kg, p.o.) +
Scopolamine (16 mg/kg, i.p.)
2.78@ ± 0.22
NSO (0.92 mg/kg, p.o.) +
Scopolamine (16 mg/kg, i.p.)
1.86@ ± 0.15
WGO (170 mg/kg, p.o.) +
Scopolamine (16 mg/kg, i.p.)
7.9*, ± 0.61
Data represent means ± SEM (n= 6). Statistical analysis was
carried out by one-way ANOVA followed by Tukey’s multiple
comparison test.
*Signiﬁcant difference from normal group at P< 0.05.
@Signiﬁcant difference from control (scopolamine) group at
P< 0.05.
Signiﬁcant difference from donepezil group at P< 0.05.
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amine is delivered systemically, therefore it cannot be excluded
that non speciﬁc factors (attentional, sensorimotor) might have
inﬂuenced rats’ performance.38 This also implies that the effects
of NSO and WGO on cognitive performance did not interfere
with sensorimotor performance of rats. NSO or WGO-treated
rats were similar to donepezil-treated rats and completely re-
versed the object recognition dysfunction induced by scopol-
amine, by reducing the time spent in exploring the familiar
object and therefore were able to discriminate between the
familiar and new object, indicating that NSO and WGO im-
proved non-spatial working memory deﬁcit in amnesic rats.
Several studies suggest that oxidative stress plays an impor-
tant role in pathogenesis of neurodegenerative disorders like
AD.39 Thus, the progression of neurodegenerative disorder
can be inhibited by the use of free radical scavengers and
anti-oxidants. MDA is an end product of lipid peroxidation;
a measure of free radical generation. GSH is an essential tri-
peptide, an antioxidant found in all animal cells. It reacts with
the free radicals and can protect cells from singlet oxygen,
hydroxyl radical and superoxide radical damage.40,41
Pretreatment of scopolamine memory deﬁcit rats with NSO
resulted in a signiﬁcant decrease in MDA and increase in GSH
brain contents to be similar to that observed in the donepezilgroup. The present ﬁndings imply the neuroprotective action
of NSO through its signiﬁcant antioxidant activity against sco-
polamine-induced oxidative stress. NSO, known as an antiox-
idant agent, ameliorated oxidative injury in the tissues and
functional deteriorations.42 The maintenance of normal GSH
level was also reported to be important for acquisition of
spatial memory since GSH unavailability induced failures in
hippocampal synaptic plasticity mechanisms that were related
to spatial memory deﬁcits.43
WGO resulted in a signiﬁcant increase in brain GSH con-
tent to be similar to the donepezil group. This ﬁnding is in har-
mony with previous results which reported that vitamin E is a
major antioxidant in biological systems44 that can prevent or
decrease the harmful effects of oxidative stress in different tis-
sues.45,46 The current ﬁnding supports the notion that antiox-
idants are considered to be a promising approach to
neuroprotection against AD.47
Administration of donepezil prior to scopolamine in this
study did not alter cholinesterase activity as compared to
scopolamine control group. This ﬁnding is in conformity with
previous study,48 conﬁrming that selective AChEIs do not alter
BChE activity.
NSO treated scopolamine group did not show any change
in cholinesterase activity when compared with scopolamine
Effect of Nigella sativa and wheat germ oils on scopolamine-induced memory impairment in rats 87and donepezil groups. However, it still shared comparable
memory enhancing effects in the T maze alternation task and
object recognition test, suggesting that NSO enhances memory
in this model possibly through mechanism(s) independent of
the cholinesterase enzyme inhibition as its neuroprotective ef-
fects against beta amyloid (Ab) toxicity may play a potential
role in preventing AD progression.49
The results of WGO treated scopolamine group showed sig-
niﬁcant decrease in cholinesterase activity as compared to con-
trol scopolamine group. This study is in agreement with
previous ﬁndings which demonstrated that rats pretreated with
vitamins E and C prevented Arginine induced alteration of
BChE activity in serum of rats.50 Inhibition of BChE may de-
lay plaque formation and enhance the magnitude of long term
potentiation,51 thus suggesting the possibility to use WGO as
butyrylcholinesterase inhibitor (BChEI) in the treatment of
AD not only to increase the availability of acetylcholine at
the synapses, but also to reduce the number of plaques and in-
crease synaptic plasticity.
TNF-a has been postulated to be an important mediating
factor in the neurodegeneration seen in AD52 and may contrib-
ute to cognitive dysfunction and accelerated progression of
AD.53
Treatment with NSO before scopolamine signiﬁcantly de-
creased TNF-a brain content to a level similar to that observed
in the donepezil group. Thymoquinone (TQ) the main active
principle in NSO has been reported to be effective against tran-
sient forebrain ischemia-induced inﬂammation in the rat hippo-
campus.54 In this study, it is likely that scopolamine-induced
oxidative stress may lead to inﬂammation. These ﬁndings imply
that NSO mitigated scopolamine-induced memory impairment
through its anti-inﬂammatory action probably via an anti-oxi-
dative mechanism.
WGO resulted in a signiﬁcant increase in TNF-a content
when compared to that of donepezil group. This ﬁnding sug-
gests that WGO cognitive enhancing effect in this model
may be possibly via mechanism(s) independent on inhibition
of elevated TNF-a brain content as it was reported that vita-
min E supplementation reduced Ab deposition in a young
transgenic mouse model of AD (Tg2576).55
In conclusion, both NSO and WGO exerted cognitive
enhancing effects against scopolamine-inducedmemory impair-
ment in rats. Therefore, their use might offer a useful therapeu-
tic choice in either prevention or treatment of AD.References
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